A pilot open label randomized controlled study to evaluate the dose tolerance safety and efficacy of VT-122 regimen for the treatment of cachexia in subjects with stage IV non-small cell lung cancer
Phase of Trial: Phase II
Latest Information Update: 22 May 2013
At a glance
- Drugs Propranolol/etodolac (Primary)
- Indications Cachexia
- Focus Therapeutic Use
- 06 May 2009 Actual end date (September 2008) added as reported by ClinicalTrials.gov.
- 06 May 2009 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
- 30 Apr 2008 The final study report is expected in June 2008, according to a media release from Vicus Therapeutics.